Tech Company Financing Transactions
Sermonix Pharmaceuticals Funding Round
Sermonix Pharmaceuticals closed a $4.2 million Seed funding round on 11/29/2017. Backers included Endoceutics and private investors.
Transaction Overview
Company Name
Announced On
11/29/2017
Transaction Type
Venture Equity
Amount
$4,200,000
Round
Seed
Investors
Endoceutics (Fernand Labrie)
private investors (Richard DeSchutter)
Proceeds Purpose
The company will use the financing round to fund ongoing operations and prepare for entry of investigational drug lasofoxifene into a Phase II clinical trial in Estrogen Receptor Positive (ER+) Metastatic Breast Cancer.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
3000 East Main St. 218
Columbus, OH 43209
USA
Columbus, OH 43209
USA
Phone
Website
Email Address
Overview
Sermonix Pharmaceuticals is an Ohio LLC privately held biotechnology company with a targeted focus towards bringing female-specific oncology products through proof of concept, preclinical, and clinical development with a clear regulatory pathway in place.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chairman
Anthony Wild
Chief Executive Officer
David Portman
Chief Financial Officer
Lawrence Hoffman
Chief Operating Officer
Miriam Portman
Chief Scientific Officer
Barry Komm
VP - Bus. Development
Elizabeth Attias
VP - Bus. Development
Paul Plourde
Browse more venture capital transactions:
Prev: 11/29/2017: Qool Therapeutics venture capital transaction
Next: 11/29/2017: BetterLesson venture capital transaction
Share this article
Where The Data Comes From
We do our best to document tech company VC transactions. VC transactions on this site are sourced from company press releases and news coverage. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs